A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose, adaptive parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020322 following oral administration in healthy participants and chronic hepatitis B patients.

Timeline

Start

2015-11-28

Primary completion

2016-05-09

Completion

2016-05-09

Outcome

Outcome not reported

Stopped: “Molecule Development was Terminated”

Publications

• Misumi I, Yue Z, Jiang Z, Karampoori A, Whitmire JK, Cullen JM, Block T, Lemon SM, Du Y, Li Y. Hepato-selective dihydroquinolizinones active against hepatitis A virus in vitro and in vivo. Antiviral Res. 2025 May;237:106145. doi: 10.1016/j.antiviral.2025.106145. Epub 2025 Mar 19.

Drugs

Indications